title: Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.
abstract: The aim of the study was to determine whether atherosclerotic risk markers exist at the moment and after withdrawal of cabergoline (CAB) therapy in patients who had taken a suitable dose of CAB therapy for a suitable period of time before cessation of CAB.
  
  
  
  This study was designed as prospective cross-sectional. Out of a total of 115 patients with prolactinoma, 42 non-obese women with microprolactinoma, who met the Pituitary Society criteria (2006) for the withdrawal of long-term CAB therapy, and 30 healthy patients participated in our study. The number of patients excluded from the study were as follows: 34 patients with tumor shrinkage of less than 50%; 10 who received DA treatments for less than 2 years; 9 who were treated with bromocriptine; and 20 who had diabetes mellitus, hypertension, hyperlipidemia, obesity, renal disease, coronary arterial disease, or were tobacco smokers. The patients were evaluated for anthropometric, metabolic, and inflammatory parameters at the time of cessation of CAB therapy and at the 3rd and 12th months after the withdrawal of CAB therapy. Endothelial dysfunction was determined by flow-mediated dilation (FMD) of the brachial artery and carotid intima media thickness (IMT), which were assessed by high resolution ultrasonography (USG) by the same practitioner.
  
  
  
  At the moment of cessation of CAB therapy, the FMD percentage in patients with prolactinoma was worse than that in healthy controls (p=0.0029). After the withdrawal of CAB treatment, fibrinogen (p=0.036), mean platelet volume (MPV) (p<0.001), carotid IMT (p=0.041), and high-density lipoprotein cholesterol (HDL C) (p=0.048) were worse in the relapse patients than those in the remission patients. Furthermore, only MPV values were found to be significantly related to a relapse of hyperprolactinemia among all atherosclerotic risk markers [area under the curve: 0.830 (95% CI 0.685-0.974) (p<0.001)].
  
  
  
  Unfavorable cardiovascular risk profiles are a problem for patients with prolactinoma during cessation and after CAB withdrawal.
authors.affiliation: Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital; Ankara-Turkey. bercemay@gmail.com.
authors.forename: Berçem Ayçiçek
authors.initials: BA
authors.lastname: Doğan
authors.forename: Ayşe
authors.initials: A
authors.lastname: Arduç
authors.forename: Mazhar Müslüm
authors.initials: MM
authors.lastname: Tuna
authors.forename: Narin Imga
authors.initials: NI
authors.lastname: Nasıroğlu
authors.forename: Serhat
authors.initials: S
authors.lastname: Işık
authors.forename: Dilek
authors.initials: D
authors.lastname: Berker
authors.forename: Serdar
authors.initials: S
authors.lastname: Güler
mesh_terms: D000293:Adolescent; D000328:Adult; D050197:Atherosclerosis / Q000209:etiology*; D001916:Brachial Artery; D000077465:Cabergoline; D059168:Carotid Intima-Media Thickness; D003430:Cross-Sectional Studies; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011388:Prolactin; D015175:Prolactinoma / Q000188:drug therapy*; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline